Overview
- Research firm Pharmarack reported Mounjaro led October sales by value at $11.38 million.
- Mounjaro’s October consumption was about 10 times higher than Novo Nordisk’s Wegovy by volume, according to the same data.
- Wegovy, launched in June, has generated more than $37 million in revenue through the end of October.
- Mounjaro is a once‑weekly injectable that targets GLP‑1 and GIP receptors and costs roughly ₹14,000 to ₹17,500 per month in India.
- India’s anti‑obesity drug market reached ₹628 crore in the 12 months to June 2025, and IMARC projects expansion to about ₹25,000 crore by 2030.